(NASDAQ: TENX) Tenax Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.03%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.06%.
Tenax Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast TENX's revenue for 2025 to be $3,916,490, with the lowest TENX revenue forecast at $3,916,490, and the highest TENX revenue forecast at $3,916,490. On average, 1 Wall Street analysts forecast TENX's revenue for 2026 to be $16,273,016, with the lowest TENX revenue forecast at $16,273,016, and the highest TENX revenue forecast at $16,273,016.
In 2027, TENX is forecast to generate $274,878,851 in revenue, with the lowest revenue forecast at $274,878,851 and the highest revenue forecast at $274,878,851.